Produktbild: Pharmaceutical and Medical Device Safety

Pharmaceutical and Medical Device Safety A Study in Public and Private Regulation

Fr. 131.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

21.02.2019

Verlag

Bloomsbury

Seitenzahl

322

Maße (L/B/H)

24.4/17/1.9 cm

Gewicht

713 g

Sprache

Englisch

ISBN

978-1-5099-1669-6

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

21.02.2019

Verlag

Bloomsbury

Seitenzahl

322

Maße (L/B/H)

24.4/17/1.9 cm

Gewicht

713 g

Sprache

Englisch

ISBN

978-1-5099-1669-6

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Pharmaceutical and Medical Device Safety
  • 1. Introduction
    I. The Legal Context
    A. Basis of Liability
    B. Litigation Systems
    C. Funding and Costs
    D. US: The Class Action and MDL
    E. Europe
    F. Settlement Schemes

    2. The Regulation of Medicines and Medical Devices
    I. Medicinal Products
    A. Historical Drug/Pharmaceutical Regulation in the UK
    B. European Regulation of Medicinal Products
    C. European Regulation of Medical Devices
    D. General Product Safety Regulation in Europe
    E. Medicinal Product Regulation in the US
    F. US Regulation of Medical Devices

    3. Detailed Case Descriptions and Regulatory Histories
    I. Teratogens and Foetal Damage
    A. Thalidomide (alpha-phthalimido-glutarimide)
    B. Hormonal Pregnancy Tests - Including Primodos
    C. Diethylstilboestrol (DES)
    D. Epilim/Depakote/Depakene (sodium valproate, valproic acid, magnesium valproate, valproate semisodium or valpromide)
    E. Accutane/Roaccutane (isotretinoin)
    II. Contraceptives and Hormone Replacement Therapy
    A. Gravigard or Copper 7 Intrauterine Device
    B. Third-Generation Oral Contraceptives
    C. Norplant (levonorgestrel)
    D. Hormone Replacement Therapy
    III. Vaccines
    A. DTP Vaccine
    B. MMR Vaccine
    IV. Neuromodulators
    A. Benzodiazepines
    B. Merital (nomifensine)
    C. Selective Serotonin Reuptake Inhibitors
    D. Sabril (vigabatrin)
    E. Mirapexin/Sifrol/Daquiran (pramipexole)
    V. Non-Steroidal Anti-Inflammatories
    A. Opren (benoxaprofen)
    B. Vioxx (rofecoxib)
    VI. Pancreatic Function (Endocrine and Exocrine) and Obesity Treatments
    A. Adifax/Isomeride/Redux (dexfenfluramine) and Ponderax (fenfluramine)
    B. Mediator (benfluorex)
    C. Human Insulin
    D. Pancreatic Enzymes
    VII. Contaminated Human-Tissue-Derived Products
    A. Blood Products
    B. Human Growth Hormone
    VIII. Cardiovascular Pharmaceuticals
    A. Eraldin (practolol)
    B. Manoplax (flosequinan)
    C. Lipobay (cerivastatin)
    IX. Anti-Protozoan Medications
    A. Emaform, Entero-Form or Chinoform (clioquinol)
    B. Lariam (mefloquine)
    X. Breast and Other Cosmetic Implants
    A. Dow-Corning Silicone Implants
    B. Trilucent Breast Implants
    C. Poly Implant Prothese (PIP) Hydrogel Breast Implants
    D. Poly Implant Prothese (PIP) IMGHC Silicone Breast Implants
    XI. Urinary Incontinence and Pelvic Prolapse Treatments
    A. Micturin (terodiline)
    B. Urogynaecological Mesh

    4. Conclusions
    I. Prevention is Better than a Cure
    II. Adverse Event Reporting
    III. Correlation or Causation?
    IV. Thresholds
    V. Product Withdrawals
    VI. Compensation or Redress?
    VII. Public Regulation v Private Regulation
    A. Compensation - Redress
    B. Deterrence
    VIII. Conclusions